Wall Street Trader schreef op 5 dec 2019 om 10:47:
In the field of inflammation, few drugs work in only one indication and ABX464 is already investigated in two other ones with phase II trials just starting or about to start in rheumatoid arthritis (RA) and Crohn’s disease(CD).
There is a bit more work to do here but the rationale to see ABX464 working is quite high although lower PoS are deserved.
Time has come for Abivax to consider extracting value from ABX464 either by partnering it to a large pharmaceutical company that will leverage its potential in all possible markets or by selling the whole company since ABX464 represents most of it. Most because a first-in-class candidate in oncology has started the first part of a phase I/II study, in combination with nivolumab in HCC.
UC alone offers a significant upside to the current valuation.
But because ABX464 cannot be split in parts, it will be either partnered or sold to a third party that will recognize its value across its full range of potential indications. We strongly recommend to buy the stock.